# US 2026/0098083 A1 · Novel Antibody For Prevention Or Treatment Of Fibrotic Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098083 A1
- Document ID: US20260098083A1
- Status: Published application
- Kind: A1
- Application number: 19/112,732
- Filed: 2023-09-20
- Published: 2026-04-09
- Earliest claimed: 2022-09-21
- Assignees: Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Hogeun YOON; Soo-Yeon PARK
- Web page: https://patentgrep.com/patent/US20260098083A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 11/00: Drugs for disorders of the respiratory system
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/12: Pulmonary diseases
- G01N 2800/7052: Fibrosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method for prevention or treatment of fibrotic disease, wherein an antibody binding specifically to Asporin protein involved in fibrosis is used for predicting the onset of fibrotic disease or for inhibiting the activity of the corresponding protein. The present invention provides an effective antibody that can be used for the diagnosis, prevention, and treatment of idiopathic pulmonary fibrosis, a condition for which efficient treatment methods have been absent because a clear pathogenic mechanism is not known therefor. In addition, the present invention can be advantageously used to effectively block fibrosis in various tissues by ultimately providing a fundamental inhibitory method for pathological fibrosis mechanisms.

## Claims

### Claim 1

An antibody to Asporin protein, or an antigen-binding fragment thereof, comprising a heavy chain variable region having a heavy chain complementarity determining region (CDR) amino acid sequence of HCDR1 having the sequence of SEQ ID NO: 1, HCDR2 having the sequence of SEQ ID NO: 2, and HCDR3 having the sequence of SEQ ID NO: 3.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:11.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment further comprises a light chain variable region having the light chain CDR amino acid sequence of LCDR1 having the sequence of SEQ ID NO:4, LCDR2 having the sequence of SEQ ID NO:5, and LCDR3 having the sequence of SEQ ID NO:6.

### Claim 4 (depends on 3)

The antibody or antigen-binding fragment thereof of claim 3, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antigen-binding fragment is a Fab fragment, an F(ab′) fragment, an F(ab′)2 fragment, or an Fv fragment.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 7 (depends on 1)

A method for preventing or treating fibrotic disease, comprising administering a composition comprising an antibody or an antigen-binding fragment thereof as an active ingredient, as defined in claim 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the fibrotic disease is a disease selected from the group comprising liver fibrosis; kidney fibrosis; and pulmonary fibrosis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

### Claim 10 (depends on 1)

A nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, as defined in claim 1.

### Claim 11

(canceled)

### Claim 12

An antibody to Asporin protein, or an antigen-binding fragment thereof, comprising a light chain variable region having the light chain complementarity determining region (CDR) amino acid sequence of LCDR1 having the sequence of SEQ ID NO: 4, LCDR2 having the sequence of SEQ ID NO: 5, and LCDR3 having the sequence of SEQ ID NO: 6.
